Cargando…

Low-dose rituximab should be used for treating MS in resource-limited settings: Yes

Detalles Bibliográficos
Autores principales:	Piehl, Fredrik, Mathew, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Controversies in Multiple Sclerosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131395/ https://www.ncbi.nlm.nih.gov/pubmed/35437089 http://dx.doi.org/10.1177/13524585221089890

Ejemplares similares

Low-dose rituximab should be used for treating MS in resource-limited settings: No
por: Mateen, Farrah J
Publicado: (2022)

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes”
por: Rolfes, Leoni, et al.
Publicado: (2021)

Much, if not all, of the cortical damage in MS can be attributed to the microglial cell – Yes
por: van Wageningen, Thecla A, et al.
Publicado: (2018)

Serum MOG IgG titres should be performed routinely in the diagnosis and follow-up of MOGAD: Yes
por: Reindl, Markus, et al.
Publicado: (2023)

Presymptomatic MS or radiologically isolated syndrome (RIS) should be actively monitored and treated – NO
por: Smets, Ide
Publicado: (2023)

MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Yes
por: Scalfari, Antonio
Publicado: (2021)

Quality of life should be the primary outcome for disease modifying therapy trials in MS—No
por: Strijbis, EMM, et al.
Publicado: (2023)

Studying the blood–brain barrier will provide new insights into neurodegeneration – Yes
por: Kamphuis, Wouter W, et al.
Publicado: (2018)

4-aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect – Yes
por: Strijbis, Eva MM, et al.
Publicado: (2020)

All anti-CD20 monoclonal antibodies have similar efficacy and safety risks: Yes
por: Cree, Bruce AC
Publicado: (2022)

Anxiety is more important than depression in MS – Commentary
por: de Jong, Brigit A, et al.
Publicado: (2018)

Serum MOG-IgG titers should be performed routinely in the diagnosis and follow-up of MOGAD: Commentary
por: Gastaldi, Matteo, et al.
Publicado: (2023)

Functional training is a senseless strategy in MS cognitive rehabilitation: Strategy training is the only useful approach – NO
por: Hulst, Hanneke E, et al.
Publicado: (2017)

MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Commentary
por: Schmierer, K, et al.
Publicado: (2021)

Exposure to natalizumab during pregnancy and lactation is safe – No
por: Airas, Laura
Publicado: (2020)

T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis: No
por: Mühlau, Mark
Publicado: (2022)

Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis – Commentary
por: Hohlfeld, R
Publicado: (2021)

Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis – No
por: McMurran, Christopher E
Publicado: (2021)

Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary
por: Lycke, Jan, et al.
Publicado: (2022)

All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: No
por: Rotstein, Dalia L
Publicado: (2022)

Safety of breast feeding during rituximab treatment in multiple sclerosis
por: Rød, Brit Ellen, et al.
Publicado: (2023)

Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study
por: Smith, Kelsi A, et al.
Publicado: (2023)

Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT
por: Kvistad, Silje Agnethe Stokke, et al.
Publicado: (2022)

Delayed B cell repopulation after rituximab treatment in multiple sclerosis patients with expanded adaptive natural killer cells
por: Moreira, Antía, et al.
Publicado: (2022)

How common is truly benign MS in a UK population?
por: Tallantyre, Emma Clare, et al.
Publicado: (2019)

Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses
por: Novak, Frederik, et al.
Publicado: (2023)

Changes to anti-JCV antibody levels in a Swedish national MS cohort
por: Warnke, Clemens, et al.
Publicado: (2013)

Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations
por: König, Marton, et al.
Publicado: (2023)

Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients
por: Sejbaek, Tobias, et al.
Publicado: (2019)

Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS
por: Duan, Yunyun, et al.
Publicado: (2021)

Autologous haematopoietic stem cell transplantation versus low‐dose immunosuppression in secondary–progressive multiple sclerosis
por: Mariottini, Alice, et al.
Publicado: (2022)

Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients
por: Dahlhaus, Stefanie, et al.
Publicado: (2013)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
por: Aiello, Alessandra, et al.
Publicado: (2023)

Gadolinium should always be used to assess disease activity in MS – Yes
por: Granziera, Cristina, et al.
Publicado: (2020)

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes
por: De Stefano, Nicola, et al.
Publicado: (2014)

Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions
por: Muhlert, Nils, et al.
Publicado: (2014)

Tobacco smoking and excess mortality in multiple sclerosis: a cohort study
por: Manouchehrinia, Ali, et al.
Publicado: (2014)

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
por: Olsson, Tomas, et al.
Publicado: (2014)

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
por: Edan, G, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pcoiaeiidp4hrr38shvvtpicb5